VIII Franco Brazilian Congress of Oncology

Higher doses of fulvestrant suggest in ER breast cancer

Dr Gilberto Amorín – Brazilian Nacional Cancer Institute, Rio de Janeiro, Brazil

We have a lot of opportunity to treat the ER positive patients, even in advanced disease we have a lot of different drugs: we can use different aromatase inhibitors, we have Tamoxifen, we have also the combination with everolimus, with exemestane. But we have a great experience also to use fulvestrant. In this last, maybe, four and five years we are using this drug in the regular initial labelled dose, that is 250mg. We know that in other countries, like in Europe, like Spain, and even in the US, the United States, they are using it at double, at double of this dose, because some studies show that we have improved the results, even the survival results, with this higher dose. But recently in Brazil we have the authority opportunity approval to use this new dose that we can improve the results. So we have the opportunity to share the scientific information for the medical oncologists in Brazil. This is recent information, probably some of our colleagues in the country don’t know yet that it’s possible to use 500mg. So it’s a nice drug because we have a number of very low side effects and we have the opportunity to improve the results. So we have the opportunity to discuss this with our colleagues.